As a secondary endpoint, this study also reported some preliminary evidence of the treatment’s efficacy, since the IL−6, IL−8, MMP−9, TNF-α and TGF-β1 levels in tracheal aspirates were lower after the treatment, and MSC recipients seemed to have less severe BPD. The gene discussed is IL6; the disease is bronchopulmonary dysplasia.